Monolithic Power Systems Inc vs Moderna, Inc. — how do they compare? Monolithic Power Systems Inc trades at $1,383 (market cap $65.28B), while Moderna, Inc. trades at $59.66 (market cap $23.60B). The key difference: Monolithic Power Systems Inc is far larger — about 2.8× Moderna, Inc.'s market cap, and Monolithic Power Systems Inc pays a 0.6% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MPWR | MRNA | |
|---|---|---|
Market Cap | $65.28B | $23.60B |
Sector | Utilities | Health |
52-Week High | $1.69K | $81.80 |
52-Week Low | $711.24 | $22.36 |
Enterprise Value | $63.94B | $19.70B |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Trailing returns across standard periods
Latest headlines on both assets
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →